摘要
目的探究心元胶囊联合培哚普利治疗原发性高血压患者的疗效。方法选取2018年3月至2019年5月本院收治的64例原发性高血压患者,按照随机数表法分为A组与B组,各32例。A组采用培哚普利治疗,B组在A组基础上联合心元胶囊治疗,比较两组临床疗效、血压、血脂水平及不良反应发生率。结果B组临床治疗总有效率高于A组(P<0.05);治疗后,两组总胆固醇、三酰甘油、低密度脂蛋白、收缩压、舒张压指标均下降,且B组低于A组,高密度脂蛋白均升高,且B组高于A组(P<0.05);两组不良反应发生率比较差异无统计学意义。结论针对原发性高血压患者采用心元胶囊联合培哚普利治疗不仅可有效改善其血脂水平,而且可控制血压水平,疗效显著,安全性较高。
Objective To explore the efficacy of Xinyuan capsule and perindopril in patients with primary hypertension.Methods 64 patients with primary hypertension from March 2018 to May 2019 were selected.They were divided into group A and group B according to random number table,with 32 cases in each group.Group A was treated with perindopril,and group B was combined with Xinyuan capsule on the basis of group A.The clinical efficacy,blood pressure,blood lipid level and the incidence of adverse reactions between the two groups were compared.Results The total clinical treatment efficiency rate of group B was higher than group A(P<0.05);after treatment,the indexes of total cholesterol,triglyceride,low-density lipoprotein,systolic blood pressure and diastolic blood pressure in the two groups decreased,group B was lower than group A,highdensity lipoprotein increased,and group B was higher than group A(P<0.05);there was no significant difference in the incidence of adverse reactions between the two groups.Conclusion The use of Xinyuan capsule combined with perindopril can not only effectively improve the blood lipid level,but also control the blood pressure,with significant efficacy and high safety.
作者
赵建
ZHAO Jian(Department of Cardiology,Jinzhou Second Hospital,Jinzhou,Liaoning,121000,China)
出处
《当代医学》
2021年第25期50-52,共3页
Contemporary Medicine
关键词
原发性高血压
心元胶囊
培哚普利
血压
血脂
Primary hypertension
Xinyuan capsule
Perindopril
Blood pressure
Blood lipid
